Research Study

A Phase 3 Multicenter, RandomizeEd, Double Blind, Placebo COntrolled, Parallel Group Study to Evaluate the Safety, Tolerability, & Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium Difficile Infection (CDI) in Adults
Principal Investigator 
Theodore Steiner

Overview

ClinicalTrials.gov# 
NCT03183128
Status 
Recruiting
Study Start/End 
May 11, 2018 to Nov 30, 2018
Locations 
Diamond Health Care Centre
Name/Title 
Jorell Gantioqui, Research Coordinator
Phone 
604-875-4111 ext.62178
Purpose of Study 

The purpose of this study is to demonstrate the superiority of SER-109 vs placebo to reduce recurrence of CDI in adults up to 8 weeks after initiation of treatment.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.